RT Journal Article
T1 Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review.
A1 Cepero, Ana
A1 Luque, Cristina
A1 Cabeza, Laura
A1 Perazzoli, Gloria
A1 Quiñonero, Francisco
A1 Mesas, Cristina
A1 Melguizo, Consolacion
A1 Prados, Jose
K1 5-fluorouracil
K1 colon carcinoma
K1 monoclonal antibody
K1 nanoformulation
K1 targeted therapy
AB The failure of chemotherapeutic treatment in colorectal cancer (CRC), the second most mortal cancer worldwide, is associated with several drug limitations, such as non-selective distribution, short half-life, and development of multiple resistances. One of the most promising strategies in CRC therapy is the development of delivery systems based on nanomaterials that can transport antitumor agents to the tumor site more efficiently, increasing accumulation within the tumor and thus the antitumor effect. In addition to taking advantage of the increased permeability and retention effect (EPR) of solid tumors, these nanoformulations can be conjugated with monoclonal antibodies that recognize molecular markers that are specifically over-expressed on CRC cells. Active targeting of nanoformulations reduces the adverse effects associated with the cytotoxic activity of drugs in healthy tissues, which will be of interest for improving the quality of life of cancer patients in the future. This review focuses on in vitro and in vivo studies of drug delivery nanoformulations functionalized with monoclonal antibodies for targeted therapy of CRC.
PB Dove Medical Press Ltd.
YR 2022
FD 2022-08-21
LK http://hdl.handle.net/10668/20465
UL http://hdl.handle.net/10668/20465
LA en
NO Cepero A, Luque C, Cabeza L, Perazzoli G, Quiñonero F, Mesas C, et al. Antibody-Functionalized Nanoformulations for Targeted Therapy of Colorectal Cancer: A Systematic Review. Int J Nanomedicine. 2022 Oct 31;17:5065-5080.
NO A.C. and F.Q. to acknowledge FPU2017 and FPU2019 grants (ref. FPU17/02977 and FPU19/04112) from the Ministeriode Educación y Formación Profesional (Spain) and C.L. a P-FIS (ref. PI20-00284) from the Ministerio de Ciencia,Innovación y Universidades (Spain). This research was funded in part by Junta de Andalucía (A-CTS-666-UGR20,P20_00540, B-CTS-122-UGR20 and PYC20-RE-035 UGR) FEDER program and Instituto de Salud Carlos III(PI19/01478-FEDER).
DS RISalud
RD Apr 6, 2025